Tianjin Hanrui Pharmaceutical

Tianjin Hanrui Pharmaceutical Co., Ltd. is a high-tech pharmaceutical manufacturing company based in Tianjin, China, and operates as a production base for Tianjin Hankang Pharmaceutical Biotechnology (a subsidiary of Wuhan Hite Bio-technology). Established in 2010, the company features a comprehensive, state-of-the-art manufacturing facility built to international cGMP standards, housing seven production lines for active pharmaceutical ingredients (APIs), tablets, capsules, granules, dry suspensions, freeze-dried powder injections, and small-volume injections. In addition to its robust commercial manufacturing and contract development and manufacturing organization (CDMO) services, Tianjin Hanrui engages in the development of modified new chemical drugs, such as its candidate HKGM-452, which entered the IND application stage in 2026.